Definium Therapeutics, Inc. (DFTX) — Definium Therapeutics (the former MindMed) outlined a cluster of near-term catalysts for its DT120 (MM120, an LSD-based ODT) program, teasing three pivotal Phase 3 topline readouts.
The company pointed to the Emerge study in major depressive disorder in late Q2 2026, followed by the Voyage and Panorama studies in generalized anxiety disorder in Q3 2026. The timeline positions Definium as one of the busiest late-stage psychedelic pipelines heading into mid-2026.
Source: marketbeat.com
For the rest of that week's sector news, read our week in review.